 |
Corporate News
14-Dec-22
|
 |
|
|
|
|
|
Biocon initiates clinical study of Itolizumab for Ulcerative Colitis in India
|
|
|
|
Biocon announced the initiation of the clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc. This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC.
Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialized in handling UC cases. The first patient who intended to participate in the study was screened on 01 December 2022.
|
|
Previous News |
Stock Alert: TCS, Power Grid Corporation, NMDC, Biocon, Firstsource Solutions
(
Market Commentary
-
Stock Alert
07-Mar-25
08:31
)
|
|
Biocon signs distribution and supply agreement with Medix
(
Corporate News
-
13-May-24
09:36
)
|
|
Biocon launches GLP-1 peptide, Liraglutide in the UK
(
Corporate News
-
28-Feb-25
10:01
)
|
|
Market at day’s high; VIX climbs 3.96%; realty shares advance
(
Market Commentary
-
Mid-Session
18-Apr-24
12:37
)
|
|
Biocon inks pact with Medix to commercialize weight mgmt product
(
Hot Pursuit
-
13-May-24
08:05
)
|
|
Biocon gains after arm inks distribution agreement with Sandoz
(
Hot Pursuit
-
26-Dec-23
10:40
)
|
|
Biocon gains as arm takes over Viatris' biosimilar biz in over 70 countries
(
Hot Pursuit
-
06-Jul-23
12:03
)
|
|
Biocon consolidated net profit rises 71.09% in the June 2022 quarter
(
Results
-
Announcements
28-Jul-22
08:19
)
|
|
Biocon Ltd soars 1.76%, rises for third straight session
(
Hot Pursuit
-
06-Feb-25
13:06
)
|
|
Biocon Biologics completes integration of Viatris' biosimilars biz in over 70 countries
(
Corporate News
-
05-Jul-23
18:38
)
|
|
Biocon Q1 PAT climbs 71% YoY to Rs 144 cr
(
Hot Pursuit
-
28-Jul-22
09:53
)
|
|
|
 |
Other Stories |
 |
|
|
|
|
|
|
|